Literature DB >> 26629431

Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Katrina Woodford1, Sashendra Senthi1.   

Abstract

Entities:  

Year:  2015        PMID： 26629431      PMCID： PMC4630513          DOI： 10.3978/j.issn.2218-6751.2015.08.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  19 in total

1.  Central-airway necrosis after stereotactic body-radiation therapy.

Authors:  Michael N Corradetti; Andrew R Haas; Ramesh Rengan
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

2.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

3.  Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.

Authors:  Tingyi Xia; Hongqi Li; Qingxuan Sun; Yingjie Wang; Naibin Fan; Yong Yu; Ping Li; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

4.  Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States.

Authors:  Megan E Daly; Julian R Perks; Allen M Chen
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

5.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.

Authors:  Mojgan Taremi; Andrew Hope; Max Dahele; Shannon Pearson; Sharon Fung; Thomas Purdie; Anthony Brade; John Cho; Alexander Sun; Jean-Pierre Bissonnette; Andrea Bezjak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-04       Impact factor: 7.038

6.  Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands.

Authors:  C J A Haasbeek; D Palma; O Visser; F J Lagerwaard; B Slotman; S Senan
Journal:  Ann Oncol       Date:  2012-05-02       Impact factor: 32.976

7.  Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.

Authors:  Victor S Mangona; Andrew M Aneese; Ovidiu Marina; Richard V Hymas; Dan Ionascu; John M Robertson; Lori J Gallardo; Inga Siiner Grills
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-18       Impact factor: 7.038

8.  Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial.

Authors:  Samuel Bral; Thierry Gevaert; Nadine Linthout; Harijati Versmessen; Christine Collen; Benedikt Engels; Douwe Verdries; Hendrik Everaert; Nicolas Christian; Mark De Ridder; Guy Storme
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-12       Impact factor: 7.038

9.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

Review 10.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2013-02-22       Impact factor: 6.280
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.